CONy 2021 | Parkinson’s disease: what’s to come in 2022?

Angelo Antonini, MD, PhD, University of Padua, Padua, Italy, shares treatment strategies currently under development for Parkinson’s disease. A novel and interesting drug class, adenosine A2A receptor antagonists, is being investigated for the management of motor fluctuations. Sublingual apomorphine and inhaled levodopa are novel approaches that will soon be available. Additionally, there is an extensive effort in the development of disease-modifying therapies. Different strategies are currently being studied, such as monoclonal antibodies targeting α-synuclein, a small molecule inhibiting protein aggregation, and a kinase inhibitor. This interview was conducted during the virtual 2021 World Congress on Controversies in Neurology (CONy).